Market research
LAURUSLABS.NSE Laurus Labs Limited
NSE INR Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 1T
- P/E ratio
- 101.77
- Analyst target
- 1703.0714
- Dividend yield
- 0.0%
- Beta
- 0.34
Profile
Instrument facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- INE947Q01028
- Market cap
- 1T
- P/E ratio
- 101.77
- Analyst target
- 1703.0714
- Dividend yield
- 0.0%
- Beta
- 0.34
About
About Laurus Labs Limited
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and solid oral drug products for intermediates for anti-retroviral (ARV), anti-diabetic, cardiovascular, anti-asthma, ophthalmology, oncology, and gastroenterology. It also develops and manufactures animal-origin-free recombinant proteins and cell-culture media supplements and research and development services, including drug substance development, drug product development, and biologics development. In addition, the company offers non-human ingredients; rare disease therapeutics; and finished dosages. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.
Research context
Laurus Labs Limited appears in PyInvesting’s India Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the LAURUSLABS.NSE discussion.
5 years, 6 months ago
Laurus Labs Limited is currently in a long term uptrend where the price is trading 70.0% above its 200 day moving average.
From a valuation standpoint, the stock is 1.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.7.
Laurus Labs Limited's total revenue rose by 76.6% to $13B since the same quarter in the previous year.
Its net income has increased by 271.4% to $3B since the same quarter in the previous year.
Finally, its free cash flow grew by 137.9% to $3B since the same quarter in the previous year.
Based on the above factors, Laurus Labs Limited gets an overall score of 5/5.